Cargando…
Impact of Tumor Necrosis Factor Receptor 1 (TNFR1) Polymorphism on Dry Eye Disease
The goal of the study was to examine whether a genetic polymorphism in tumor necrosis factor receptor 1 (TNFR1) gene impacted the dry eye disease (DED) phenotype and response to anti-inflammatory therapy. The prospective study included 328 individuals with various dry eye (DE) symptoms and signs rec...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953194/ https://www.ncbi.nlm.nih.gov/pubmed/36830631 http://dx.doi.org/10.3390/biom13020262 |
_version_ | 1784893817753698304 |
---|---|
author | Acuna, Kelly Choudhary, Anjalee Locatelli, Elyana Rodriguez, Daniel A. Martin, Eden R. Levitt, Roy C. Galor, Anat |
author_facet | Acuna, Kelly Choudhary, Anjalee Locatelli, Elyana Rodriguez, Daniel A. Martin, Eden R. Levitt, Roy C. Galor, Anat |
author_sort | Acuna, Kelly |
collection | PubMed |
description | The goal of the study was to examine whether a genetic polymorphism in tumor necrosis factor receptor 1 (TNFR1) gene impacted the dry eye disease (DED) phenotype and response to anti-inflammatory therapy. The prospective study included 328 individuals with various dry eye (DE) symptoms and signs recruited from the Miami Veterans Hospital eye clinic between October 2013 and October 2017. The population underwent genetic profiling for a polymorphism within the TNFR1 gene (rs1800693 [TT, TC, CC]). The study examined the genotype distribution and relationships between the genotype, phenotype, and response to anti-inflammatory therapy. The mean age of the population was 61.7 ± 9.8 years. Here, 92% self-identified as male, 44% as White, and 21% as Hispanic; 13% (n = 42) of individuals had a CC genotype. DED symptoms and signs were similar across the three genotype groups. Thirty individuals (four with CC) were subsequently treated with an anti-inflammatory agent. There was a non-significant trend for individuals with CC genotype to have a partial or complete symptomatic response to treatment compared with the other two groups (100% for CC vs. 40% for TT and 36.4% for TC, p = 0.22). In conclusion, the presence of homozygosity of minor allele C (CC genotype) in a single nucleotide polymorphism (SNP) within TNFR1 was noted in a minority of individuals with various aspects of DED, but did not impact the DED phenotype. Our findings suggest that the current phenotyping strategies for DED are insufficient to identify underlying disease contributors, including potential genetic contributors. |
format | Online Article Text |
id | pubmed-9953194 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-99531942023-02-25 Impact of Tumor Necrosis Factor Receptor 1 (TNFR1) Polymorphism on Dry Eye Disease Acuna, Kelly Choudhary, Anjalee Locatelli, Elyana Rodriguez, Daniel A. Martin, Eden R. Levitt, Roy C. Galor, Anat Biomolecules Article The goal of the study was to examine whether a genetic polymorphism in tumor necrosis factor receptor 1 (TNFR1) gene impacted the dry eye disease (DED) phenotype and response to anti-inflammatory therapy. The prospective study included 328 individuals with various dry eye (DE) symptoms and signs recruited from the Miami Veterans Hospital eye clinic between October 2013 and October 2017. The population underwent genetic profiling for a polymorphism within the TNFR1 gene (rs1800693 [TT, TC, CC]). The study examined the genotype distribution and relationships between the genotype, phenotype, and response to anti-inflammatory therapy. The mean age of the population was 61.7 ± 9.8 years. Here, 92% self-identified as male, 44% as White, and 21% as Hispanic; 13% (n = 42) of individuals had a CC genotype. DED symptoms and signs were similar across the three genotype groups. Thirty individuals (four with CC) were subsequently treated with an anti-inflammatory agent. There was a non-significant trend for individuals with CC genotype to have a partial or complete symptomatic response to treatment compared with the other two groups (100% for CC vs. 40% for TT and 36.4% for TC, p = 0.22). In conclusion, the presence of homozygosity of minor allele C (CC genotype) in a single nucleotide polymorphism (SNP) within TNFR1 was noted in a minority of individuals with various aspects of DED, but did not impact the DED phenotype. Our findings suggest that the current phenotyping strategies for DED are insufficient to identify underlying disease contributors, including potential genetic contributors. MDPI 2023-01-31 /pmc/articles/PMC9953194/ /pubmed/36830631 http://dx.doi.org/10.3390/biom13020262 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Acuna, Kelly Choudhary, Anjalee Locatelli, Elyana Rodriguez, Daniel A. Martin, Eden R. Levitt, Roy C. Galor, Anat Impact of Tumor Necrosis Factor Receptor 1 (TNFR1) Polymorphism on Dry Eye Disease |
title | Impact of Tumor Necrosis Factor Receptor 1 (TNFR1) Polymorphism on Dry Eye Disease |
title_full | Impact of Tumor Necrosis Factor Receptor 1 (TNFR1) Polymorphism on Dry Eye Disease |
title_fullStr | Impact of Tumor Necrosis Factor Receptor 1 (TNFR1) Polymorphism on Dry Eye Disease |
title_full_unstemmed | Impact of Tumor Necrosis Factor Receptor 1 (TNFR1) Polymorphism on Dry Eye Disease |
title_short | Impact of Tumor Necrosis Factor Receptor 1 (TNFR1) Polymorphism on Dry Eye Disease |
title_sort | impact of tumor necrosis factor receptor 1 (tnfr1) polymorphism on dry eye disease |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953194/ https://www.ncbi.nlm.nih.gov/pubmed/36830631 http://dx.doi.org/10.3390/biom13020262 |
work_keys_str_mv | AT acunakelly impactoftumornecrosisfactorreceptor1tnfr1polymorphismondryeyedisease AT choudharyanjalee impactoftumornecrosisfactorreceptor1tnfr1polymorphismondryeyedisease AT locatellielyana impactoftumornecrosisfactorreceptor1tnfr1polymorphismondryeyedisease AT rodriguezdaniela impactoftumornecrosisfactorreceptor1tnfr1polymorphismondryeyedisease AT martinedenr impactoftumornecrosisfactorreceptor1tnfr1polymorphismondryeyedisease AT levittroyc impactoftumornecrosisfactorreceptor1tnfr1polymorphismondryeyedisease AT galoranat impactoftumornecrosisfactorreceptor1tnfr1polymorphismondryeyedisease |